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enrolled into the ACOS-Registry (Acute Coronary Syndrome, 154 hospitals) in Germany. 
We analysed the prospective data of STEMI-pts with special respect to the smoking sta- 
tus. 
Results: Out of 5122 consecutive pts with STEMI. 1852 (36%) were current smokers 
and 2753 (54%) had never smoked (nonsmokers). Smokers were at mean 15 years 
younger, more often male and had less often hypertension and diabetes as additional 
cardiovascular risk factors. Smokers did receive acute repelfusion therapy more often. 
The hospital mortality in nonsmokers was three times higher than in smokers. After cor- 
recting for differences in baseline characteristics and acute repedusion and adjunctive 
therapy rn a multivariate analysis smoking did not influence hospital mortality after 
STEMI (OR 0.80. 95% Cl 0.60-1.06). 
Conclusion: In smokers STEMI occurred 15 years earlier in age than in nonsmokers. In 
a multivariate analysis smoking did not influence the outcome of STEMI. 
Parameter 
Age (years) 
Male gender 
Prior MI 
Hypercholesteremia 
Hypertension 
Diabetes 
CK max (U/l) 
Acute Repedusion 
Thrombolysis 
Primary PCI 
Hospital Modality 
Smokers 
n=l852 
56 
81 .6 % 
6.4 % 
47.4 % 
45.0 % 
16.1 % 
625 
78.7 % 
26.7 % 
52.0 % 
4.7 % 
Nonsmokers 
n=2753 
71 
60.4 % 
12.8% 
40.2 % 
63.3 % 
30.5 % 
532 
64.6 % 
20.7 % 
44.1 % 
13.3 % 
p-value 
co.01 
<O.Ol 
<O.Ol 
<O.Ol 
<O.Ol 
co.01 
<O.Ol 
co.01 
<O.Ol 
<O.Ol 
co.01 
Et:45 a.m. 
869-2 Comparison of the Importance of Increasing Pathogen 
Burden, Elevated C-Reactive Protein, and the Presence 
of Antibodies to Heat Shock Protein 60 on Myocardial 
Infarction or Death 
Jianhui Zhq Stephen E. Epstein, Joseph B. Muhlestein, Javier F. Nreto, Amy 
Wasserman, Benjamin D. Home, David Rott, Jeffrey L. Anderson, Washington Hospital 
Center, Washington, DC, LDS Hospital, Salt Lake City, UT 
In addition to the importance of traditional risk factors, recent evidence suggests that 
infectious pathogens, C-reactive protein (CRP) and heat shock protein (HSP) play roles 
in the progression of atherosclerosis and can be used as outcome predictors. In the 
present study, we compared the relative importance of a) pathogen burden (seropositiv- 
iky to cytomegalovirus, hepatitis A virus, C. pneumoniae, H. pylori, herpes simplex virus 
type 1 and type 2) b) CRP levels, and c) anti-human HSPGO antibodies in predicting 
myocardial infarction (MI) or death. The patient cohorl consisted of 890 patients (77% 
men. mean age 65 years) with coronary artery disease (CAD) documented by coronary 
angiography (2 70% stenosis). The mean follow-up period was 3 years. By both univari- 
ate and Cox multivariate regression analyses, pathogen burden and elevated CRP levels 
were strong and independent predictors of incident Ml or death. The highest relative haz- 
ard was conveyed by pathogen burden (Table 1). In contrast, HSPGO antibodies were not 
significant determinants of MI or death. We conclude that in patients with documented 
CAD, both pathogen burden and elevated CRP levels are important independent predic- 
tors of MI or death, suggesting that infection and inflammation contribute to the disease 
processes leading lo acute coronary occlusion. Although HSPGO has been associated 
with angiographic evidence of the presence and extent of CAD, it’s role in the acute com- 
plications of CAD is still to be determined. 
Table 1. Comparison of Relative Hazard (95%CL) of Incident MI or Death 
Pathogen BurdenO-3 
4 
5 
6 
CRP Tadile 1 
2 
3 
HSPGO Ab (c) 
HSPGO Ab (-) 
Unadjusted Adjusted For CAD Risk Factors 
1 .o 
1.9 (0.6-4.4) 
3.2 (I .4-6.9) 
4.6 (2.1-9.9) 
1 .o 
1.9 (1.3-2.9) 
1 .Q (1.3-2.9) 
1.0 
1.2 (0.8-I .6) 
1 .o 
1.5 (0.6-3.5) 
2.6 (I .2-5.7) 
3.1 (1.4-6.8) 
1.0 
1.8 (I .2-2.6) 
1.7 (1.1-2.5) 
1.0 
1.2 (0.8-l .6) 
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869-3 Increased Concentrations of Bone Marrow-Derived 
Stem Cells in Peripheral Blood After Acute Myocardial 
Infarction 
Antonio Maria Leone, Sergio Rutella. Felicita Andreotti, Luca Pierelli, Mariaelena 
Lombardi, Giuseppe Leone, Filippo Crea, Universita Cattolica del Sacro Cuore, Rome, 
Italy 
Background: recent studies in expenmental models have shown that bone marrow- 
derived stem cells (BMSCs) can regenerate myocardial tissue after a myocardial infarc- 
tion. Moreover, the presence of cardiomyocytes of extracardiac origin has been reported 
in human transplanted heads. It is reasonable to assume, therefore, that EMSCs may be 
released into the peripheral blood after an acute myocardial infarctron (AMI). migrate 
towards the head, and there differentiate into cardiomyocytes to repas, at least in part, 
the damaged tissue. The awn of this study was to evaluate whether BMSC concentra- 
tions increase in peripheral blood after an AMI. Methods: BMSC concentratrons were 
measured by flow-Cytometry as CD34+ cellslmicroliter (mcl) rn the peripheral blood of 22 
patients with AMI after I, 3, 5 and 7 days from the event and in 11 healthy controls with- 
out cardiovascular risk factors of similar age, sex and race. Results In agreement with 
the literature, the median concentration of CD34+ cells in healthy controls was <l/mcl 
(0.47/mcl, interquartile range - IR - 0 to 0.94). In contrast, in the absence of clinical and 
laboratory findings of hemoconcentration, the median concentration of CD34+ cells in 
patients with AMI was significantly increased at 1, 3, 5 and 7 days from the event to 4.461 
mcl (IR 2.6 to 8.4, p=O.OOOS), 2.9l/mcl (IR 2.16 to 4.045, p=O.O014), 5.03imcl (IR 2.36 to 
7.9, p=O.O013). and 7.925 (IR 5.26 to 12.68, p=O.O075), respectively (Figure). Conclu- 
sions: In patients with AMI there is an increase in peripheral bone marrow-derived stem 
cell concentrations. These results support the hypothesis that these cells may migrate, 
differentiate, proliferate and contribute to remodel the infarcted myocardium. 
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869-4 Association of Left Ventricular Hypertrophy Regression 
and Heart Rate Reduction With Determinants of 
Myocardial Oxygen Consumption and Cardiovascular 
Events: The LIFE Study 
Richard B. Devereux, Kristian Wachtell, Eva Gerdts. Peter Aurup, Kurt Boman, Jonathan 
Edelman, Markku Nieminen, Vasilios Papademetriou, Ying Wan, Bjorn Dahlof. Steve 
Julius, Weill Cornell Medical Center, New York, NY 
Background: Expenmental studies have demonstrated that increased myocardral 02 
consumption demand due to left ventricular hypedrophy (LVH) increases the likekhood 
and size of myocardial infarction (Ml) with a standardized coronary occulusion, but no 
human data exist to separate the potentially beneficial effects of LVH regression and 
reduced myocardial 02 demand on the rate of Ml in treated hypertensive patients. Meth- 
ods: In a double-blind, randomized, parallel-group design 960 participants in the Losar- 
tan Intervention for Endpoint reduction in hypertension (LIFE) study (average age 66 
years, blood pressure 174198 mmHg) and ECG-documented LVH were assigned once 
daily losartan- or atenolol-based therapy and underwent echocardiography after 1.2.3,4 
and 5 years’ treatment. LV mass and the LV mass x end-systolic stress x heart rate triple 
product were measured as indices of LVH and 02 demand. Results: Blood pressure was 
reduced similarly in the two treatment arms (mean=-29.7116.2 versus -2&O/16.0 mmHg, 
NS) but heart rate fell more on atenolol (meafw7.2 versus -1.1 beats per minute, 
p<O.OOl). LV mass was reduced more in losartan than atenolol-treated patrents (mean=- 
22.0 versus -17.7 glm2, p=O.O21). In contrast, the triple product fell more on atenolol- 
based therapy (mean=-28% versus -18% p<O.OOl). In Cox regressions adjusting for 
treatment, baseline LV mass index and baseline and in-treatment pressures, each 25 g/ 
m2 lower LV mass index was associated with risk reductions (95% Cl) of 22 (5-34, 
p=O.O2)% for stroke and 33 (17-43, p=O.OOl)% for cardiovascular (CV) mortality but only 
13 (33 t0 -17, NS)% for Ml. Conclusion: Losartan-based antrhypertensive therapy 
reduced LV mass more but atenolol reduced the triple product (index of myocardial 02 
demand) by 10% more, potentially contributing to less reduction in Ml than stroke or CV 
death associated with reduction of LV mass and to less effect of losartan than atenolol on 
MI than stroke or CV death in the enhre LIFE study. 
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869-5 The Assessment of Myocardial Viability With Delayed 
Contrast Enhancement Using Computed Tomography 
Aaron So Jennifer Hadway, Jane Sykes, Gerald Wisenberg, Frank Prato, Tin-S” Pan, -3 
Ting-Yim Lee, Lawson Health Research Institute and Robarts Research Institute, 
London, ON, Canada, General Electric Medical Systems, Waukesha, WI 
Background: Delayed enhancement of contrast has emerged as the most popular MRI 
approach to detect ischemic injury to myocardium. We have developed a CT technique 
for the quantitative measurement of myocardial distribution volume (MDV) of contrast 
media using retrospective ECG gated tine scanning. 
Methods: Four 15-25 kg beagles were used for the study. For MDV measurement, a 30 
s baseline (without contrast) tine scan was performed in synchrony with ECG recording 
using a General Electric Medical Systems (GEMS) Lightspeed multi-slice CT scanner. 
Contrast (Omnipaque, 225 mgllml) was then constantly infused for 30-60 min before the 
scan was repeated. Images were reconstructed with half-scan data (330 ms) at 0.1 S 
interval and those at end-diastole (ED) were selected with SmartScore (GEMS) and 
averaged with CT Perfusion 2 (GEMS). MDV maps were generated by subtracting the 
averaged non-contrast enhanced ED images from the corresponding averaged constant 
infusion images. The difference images were normalized to the enhancement in the 
